Mallinckrodt Adds New Drugs With $1.2 Billion Sucampo Deal

(Bloomberg) -- Mallinckrodt Plc agreed to buy Sucampo Pharmaceuticals Inc. for about $1.2 billion in cash to add a treatment for constipation and experimental medicines targeting rare diseases, hel...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.